AstraZeneca PLC (AZN)vsQuest Diagnostics Incorporated (DGX)
AZN
AstraZeneca PLC
$186.58
-1.45%
HEALTHCARE · Cap: $263.78B
DGX
Quest Diagnostics Incorporated
$250.81
-0.40%
HEALTHCARE · Cap: $27.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 418% more annual revenue ($61.37B vs $11.84B). AZN leads profitability with a 17.0% profit margin vs 9.5%. AZN appears more attractively valued with a PEG of 1.22. DGX earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy62
out of 100
Grade: C+
DGX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$186.58
$8.38 discount
Margin of Safety
-87.2%
Fair Value
$111.82
Current Price
$250.81
$138.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Earnings expanding 28.7% YoY
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : DGX
The strongest argument for DGX centers on EPS Growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : DGX
The primary concerns for DGX are PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a mature stock while DGX is a value play — different risk/reward profiles.
DGX carries more volatility with a beta of 0.54 — expect wider price swings.
DGX is growing revenue faster at 10.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
DGX scores higher overall (64/100 vs 62/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Quest Diagnostics Incorporated
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?